Antimicrobial resistance (AMR) is an escalating global health challenge that threatens the effectiveness of life-saving treatments and routine medical procedures. As bacteria and other pathogens evolve to resist existing drugs, infections that were once easily treatable are becoming increasingly difficult—and sometimes impossible—to cure. With estimates suggesting that AMR could cause up to 10 million deaths annually by 2050, there is an urgent need to develop new therapies, reimagine antibiotic stewardship, and strengthen global surveillance systems. Addressing AMR is not only a medical necessity but a societal responsibility that requires coordinated action across sectors and borders.
As part of our commitment to combating this crisis, we support early-stage research across laboratories in India aimed at understanding AMR and developing innovative solutions. Our funded projects span a range of approaches to tackle hard-to-treat forms of tuberculosis, including strategies targeting dormant bacterial populations and interventions that disrupt bacterial metabolism to render existing treatments more effective.
Through these efforts, we aim to accelerate scientific breakthroughs that can slow the spread of AMR and safeguard public health.
Preclinical evaluation and development of FDA-approved antipsychotic phenothiazine as a drug reposition candidate against Japanese Encephalitis (Phase 1)